Research price & evidence comparison

Melanotan I
vs Melanotan II.

Melanotan I and Melanotan II are easy to confuse in search results, abbreviations, and seller menus. This comparison resolves the exact seller-labelled identity first, then shows the current 10 mg US research-listing footprint, vendor overlap, public-document access, availability, and price dispersion for each separate board.

2shared seller pages
Same10 mg / 10 mg board sizes
5rows with public evidence routes
0clinical or effect rankings
Identity before price

Two records, kept separate.

Melanotan I is categorized as a synthetic linear alpha-melanocyte-stimulating hormone analogue research material, while Melanotan II is categorized as a synthetic cyclic melanocortin analogue research material. The roman numeral is an identity field, not a minor product variation.

Peptide Local editorial vial illustration for the Melanotan I 10 mg research price board. Not a seller product.
Peptide Local editorial visualPubChem identity record Illustration only - not a seller product, supplied vial, composition claim, or photograph of the compared listings. Confirm identity on the linked record.
Peptide A · Melanocortin analogues

Melanotan I

Synthetic linear alpha-melanocyte-stimulating hormone analogue research material

MT-IMT1Afamelanotide
Open the 10 mg price board
Peptide Local editorial vial illustration for the Melanotan II 10 mg research price board. Not a seller product.
Peptide Local editorial visualPubChem identity record Illustration only - not a seller product, supplied vial, composition claim, or photograph of the compared listings. Confirm identity on the linked record.
Peptide B · Melanocortin analogues

Melanotan II

Synthetic cyclic melanocortin analogue research material

MT-IIMT2Melanotan 2
Open the 10 mg price board
Like-for-like fields

Commercial footprint, side by side.

Price ranges use rows marked in stock. “Public evidence route” means a seller exposed a document link; it does not establish authenticity, chain of custody, purity, sterility, or vial contents.

Comparison fieldMelanotan IMelanotan II
Editorial familyMelanocortin analoguesMelanocortin analogues
Seller-listed identitySynthetic linear alpha-melanocyte-stimulating hormone analogue research materialSynthetic cyclic melanocortin analogue research material
Nominal board size10 mg10 mg
Available list range$29.99–$49.00$36.99–$37.99
Median available price$31.84$37.49
Lowest available / mg$3.00$3.70
Available rows3 of 42 of 3
Public evidence routes3 rows2 rows
Evidence only on request1 rows1 rows
Available-price spread63%3%
Snapshot checkedAug 22, 2026Aug 22, 2026
Unit warning

Per-milligram figures normalize the seller’s nominal quantity only. They are not a cross-compound value, potency, effect, or dose comparison.

Seller overlap

Where the current boards intersect.

The two names share a melanocortin family and nearly identical shorthand, so exact-domain seller pages and explicit I-versus-II labels are necessary to prevent price or evidence from being assigned to the wrong material.

Shared sellers2
  • Pepta Labs
  • Purgo Labs
Melanotan I only2
  • Core Peptides
  • Pax Peptide
Melanotan II only1
  • Onyx BioLabs
Three reading rules

What keeps this comparison honest.

  1. 01

    Treat MT-I, Melanotan 1, MT-II, and Melanotan 2 as search aliases that still require exact resolution.

  2. 02

    Do not transfer an availability state, batch report, or seller claim from one numeral to the other.

  3. 03

    The approved SCENESSE medicine record is a separate product and evidence lane from either research board.

Official context boundary

Read the source behind each category note.

These official context records explain why Peptide Local keeps research listings outside medical and approved-product lanes. They do not certify any seller or material.

Melanotan I

Afamelanotide is the active ingredient in FDA-approved SCENESSE, a 16 mg prescription implant with a specific indication, label, dosage form, and regulated supply chain. These seller-labelled 10 mg research vials are not approval-equivalent.

Read the current SCENESSE label
Melanotan II

FDA lists Melanotan II among bulk substances that may present significant safety risks in compounding and describes reports of serious adverse events plus insufficient information to establish safety for human administration.

Read the FDA source
Continue comparing

Follow the evidence, not a winner badge.

Change either peptide in the comparison tool Compare the sellers behind these rows Calculate landed cost per nominal mg Check the evidence-status boundary